Experience after 100 patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

作     者：Ingmar Knigsrainer Derek Zieker Jrg Glatzle Olivia Lauk Julia Klimek Stephan Symons Bjrn Brücher Stefan Beckert Alfred Knigsrainer 

作者机构：Department of SurgeryUniversity of TübingenHoppeSeyler-Strasse 3D-72076 TübingenGermany Center for Bioinformatics TübingenSand 14D-72076 TübingenGermany 

出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)

年 卷 期：2012年第18卷第17期

页      面：2061-2066页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：肿瘤细胞 热化疗 治疗 腔内 选择标准 多式联运 PCI CRS 

摘      要：AIM:To investigate perioperative patient morbidity/mortality and outcome after cytoreductive surgery(CRS) and hyperthermic intraperitoneal chemotherapy(HIPEC).METHODS:Of 150 patients 100 were treated with cytoreductive surgery and HIPEC and retrospectively *** and postoperative follow-up data were *** mass index(BMI),age and peritoneal carcinomatosis index(PCI) were chosen as selection criteria with regard to tumor-free survival and perioperative morbidity for this multimodal ***:CRS with HIPEC was successfully performed in 100 out of 150 *** patients were excluded because of intraoperative *** PCI was 17(1-39).In 89% a radical resection(CC0/CC1) was *** patient died postoperatively due to multiorgan *** PCI,age nor BMI was a risk factor for postoperative complications/outcome according to the DINDO *** 9% Re-CRS with HIPEC was performed during the follow-up ***:Patient selection remains the most important *** PCI,age nor BMI alone should be an exclusion criterion for this multimodal therapy.